OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (March 2020)
22 slides from OncoSec Medical's investor presentation, March 2020
Slide 1: Powerful, Tumor-agnostic Immunotherapy Treatment
Powerful, Tumor-agnostic Immunotherapy Treatment NASDAQ: ONCS ONCOSEC’S PLATFORM TO ATTACK VISCERAL, CUTANEOUS AND SUBCUTANEOUS TUMORS MARCH 2020
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS To the extent statements contained in the following retain key scientific or management personnel; (viii) the presentations are not descriptions of historical facts anticipated timing of clinical data availability; (ix) the regarding OncoSec Medical Incorporated, they shou
Slide 3: OncoSec at a Glance
OncoSec at a Glance We are a late-stage biotechnology company developing novel immunotherapy cancer treatments using our proprietary electroporation gene delivery platform. • Headquarters: Pennington, NJ, with R&D Laboratories in San Diego, CA • Ticker: NASDAQ: ONCS • Market Cap (as of 3/20/20): ~$3
Slide 4: The Promise of Immunotherapy Has Yet to Be Fully Realized
The Promise of How Checkpoint Inhibitors Work Immunotherapy Has Yet 1 Molecular switches known as checkpoints normally prevent T-cells to Be Fully Realized from attacking healthy tissue When these checkpoints, such as PD-1 2 and PD-L1, are hijacked by cancer cells, the immune system’s T-cell respons
Slide 5: Checkpoint Non-response in 60-90%
Checkpoint Powerful drugs (like KEYTRUDA®) have been highly Non-response successful for some patients, but not the majority in 60-90% 90% of cancers are solid tumors. Of these: of Cases % OF CHECKPOINT TUMOR TYPE NON-RESPONDERS MELANOMA ˜60-80% ~30% ~70% Hot Tumors Cold Tumors TRIPLE NEGATIVE BREAST
Slide 6: TAVO is Capable of Reversing Resistance to Checkpoint Therapies
TAVO (plasmid-based interleukin-12) is administered locally TAVO™ is Capable of at the tumor site using OncoSec’s electroporation gene delivery system. TAVO is designed to induce local expression of IL-12, turning “cold” tumors “hot” and Reversing Resistance enabling checkpoint therapies to be effec
Slide 7: Benefits of Electroporation (EP) Gene Delivery System
Benefits of Electroporation (EP) Gene Delivery System Rapid Transfection Versatile More rapid than Wide array of molecules can A non-invasive, traditional chemical or biologic cell transfection be transfected, and can be applied to a broad selection non-chemical, techniques of cell types non-toxic m
Slide 8: Seamless Delivery of Plasmid IL-12 + Energy
Seamless Delivery of Plasmid IL-12 + Energy Step 1: TAVO™ Injection Multiple copies of IL-12 coded DNA plasmids to produce immune modulatory proteins are injected directly into the tumor using a conventional needle and syringe. Step 2: Applicator Insertion The applicator’s tip needle array is insert
Slide 9: Pipeline is Well Diversified with Multiple Growth Opportunities
Pipeline is Well Diversified with Multiple Growth Opportunities REGIMEN TRIAL INDICATION N PARTNER PHASE 1 PHASE 2 PIVOTAL TAVO + pembrolizumab KEYNOTE-695 Advanced Melanoma ~100 TAVO™ TAVO + pembrolizumab KEYNOTE-890 Triple Negative Breast Cancer (TNBC) ~25 OMS-131 Squamous cell TAVO + epacadostat
Slide 10: Leveraging World Class Strategic Partnerships to Enhance Pipeline Value
Leveraging World Class Strategic Partnerships to Enhance Pipeline Value We are partnering with Merck Emerge collaboration provides Our partnership with CGP gives Through our partnership with on several KEYNOTE clinical Australian metastatic us the ability to develop and Sirtex, we have access to top
Slide 11: US Market Opportunity
US Market Focusing First on Metastatic Melanoma Opportunity in the United States 91,000 diagnosis 9,000 deaths each year each year 90% of all cancer cases are solid tumors Incidence of melanoma US melanoma market on the projected to almost 1.6M new cases of solid tumors in the US rise (1.4% yearly f
Slide 12: FDA Fast Track KEYNOTE-695
FDA Fast Track KEYNOTE-695 Ongoing pivotal trial in PD-1 checkpoint resistant metastatic melanoma provides a pathway towards accelerated approval GRANTED FAST TRACK AND ORPHAN DRUG DESIGNATIONS Fast-track makes Program for patients Must meet TAVO™ eligible for with no FDA RECIST (tumor accelerated a
Slide 13: Metastatic Melanoma
P R E L I M I N A R Y D ATA KEYNOTE-695 STUDY EVALUATING Metastatic Melanoma 100 PATIENTS - ONGOING TAVO™ + KEYTRUDA® (pembrolizumab) for Checkpoint Refractory Metastatic/Recurrent Melanoma 4 PRs and 1 CR out Durable responses Responders are Responders of 21 patients observed patients with bulky dem
Slide 14: Metastatic TNBC
P R E L I M I N A R Y D ATA KEYNOTE-890 STUDY EVALUATING Metastatic TNBC Rapid tumor reduction 25 PATIENTS – FULLY ENROLLED TAVO™ + KEYTRUDA® (pembrolizumab) for metastatic TNBC of 20% or greater at 3 previously treated with chemotherapy +/- CPI month evaluation 4 PRs and 3 SDs with tumor Patients a
Slide 15: TAVO is Tumor Agnostic
FUTURE OPPORTUNITIES TAVO™ is Tumor Agnostic Renal Cell Ovarian Head/Neck Carcinoma Triple Negative Bladder Colorectal Giving life to the promise of Pancreatic Breast immunotherapies across cancer types HI Few cancers are highly infiltrated or “HOT” - most LYMPHOCYTES fall on a spectrum from warm (c
Slide 16: The Power of TAVO for Visceral Lesions
The Power of INTRODUCING THE VLA: Visceral Lesion Applicator TAVO™ for Visceral Lesions Pioneering technology designed to target and treat Flexible catheter- based applicator Rigid trocar-based applicator tumors located deep inside the body CAN BE USED WITH Endoscope Bronchoscope Lower voltage Apoll
Slide 17: CGP-Sirtex Strategic Transaction
CGP-Sirtex Strategic Transaction KEY HIGHLIGHTS: • On 2/10/2020, OncoSec received a $30M cash infusion from China Grand Pharmaceutical (CGP) and its affiliate Sirtex at $2.50 per share - a significant premium to the then market price of $1.64 • OncoSec granted CGP an exclusive license to develop, ma
Slide 18: Anticipated Milestones
Anticipated Milestones Close $30 million strategic financing and partnership with CGP and Sirtex Complete enrollment and provide preliminary data update in KEYNOTE-890 study in metastatic triple negative breast cancer (TNBC) Complete enrollment in pivotal KEYNOTE-695 study for checkpoint resistant m
Slide 19: Strong Financial Position to Drive TAVO Development Forward
Strong Financial Position to Drive TAVO™ Development Forward $9.3M 10,752,529 Cash & Equivalent as of Total Shares Outstanding as of 1/31/20 1/31/20 $30M 12,000,000 Gross Proceeds Received Total Shares of Common Stock Sold from CGP/Sirtex Strategic in CGP/Sirtex Strategic Transaction Transaction on
Slide 20: Established Biotech Leaders
BOARD OF DIRECTORS Established Biotech Leaders Daniel J. O’Connor, JD WITH A TRACK RECORD OF SUCCESS Chief Executive Officer & Director Avtar Dhillon, M.D. Co-Founder/Chairman MANAGEMENT Chao Zhou Director Daniel J. O’Connor Kellie Malloy Foerter Yuhang Zhao, Ph.D., M.B.A. President/Director/CEO Chi
Slide 21: OncoSec is Positioned for Success with TAVO
OncoSec is Positive tumor Well tolerated, natural Positioned shrinkage/response data being generated by our lead pipeline solution to increase the efficacy of checkpoint for Success with product, TAVO, across multiple solid tumor types therapies TAVO™ Expanding device Fast track status and developme
Slide 22: Thank You
Thank You Gem Hopkins HEAD OF CORPORATE COMMUNICATIONS 858.210.7334 ghopkins@oncosec.com HEADQUARTERS SCIENTIFIC LAB & RESEARCH 24 NORTH MAIN STREET 3565 GENERAL ATOMICS CT. PENNINGTON, NJ SAN DIEGO, CA